$BSX

Boston Scientific reported Q3 Non-GAAP EPS of $0.73, beating estimates by $0.01, with revenue of $5.14B, up 1.4% year-over-year. The company reduced its 2026 guidance, citing a cyberattack's impact on sales, with adjusted EPS forecasted at $3.16–$3.18, below the consensus of $3.23.

BOSTON SCIENTIFIC CORP (BSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Boston Scientific announces results for third quarter 2026 Marlborough, Mass. (October 28, 2026) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, operation

Costa Rica received $5.12B in foreign direct investment in 2025, with 54.8% from the U.S. Medical devices were the largest export. Key investors include Boston Scientific, Medtronic, Intel, and Bayer. The free-zone regime, offering tax incentives, attracted 66.4% of investments. The U.S. is the top trading and security partner, while China, the IMF, and the World Bank have narrower roles.

Stifel reduced its price target for Boston Scientific (BSX) to $55 from $60, citing the impact of a cyberattack. The company expects material effects on Q3 2026 and full-year 2026 results, leading to lower revenue projections and revised earnings estimates. Analysts remain divided, with some maintaining buy ratings and others lowering targets due to competitive pressures.

Analysts maintained Buy ratings on Relay Therapeutics (RLAY), Boston Scientific (BSX), and Palisade Bio (PALI). Price targets set at $25 for RLAY, $66 for BSX, and $7 for PALI. All three have Strong Buy consensus ratings.

On October 21, 17 ETFs added shares of Boston Scientific (BSX) totaling $23.9 million, extending a three-day streak of net inflows. The largest buyers were CGGO, IHI, and SPYM. BSX operates in the medical devices sector with a market cap of $66.7 billion. ETFs have been net buyers of BSX in 3 of the last 5 days.

Boston Scientific Corp. shares rose 3.37% to $46.01 on Thursday, outperforming the broader market. The stock remains 56.45% below its 52-week high of $105.65. The Dow Jones Industrial Average gained 0.02%, while the S&P 500 fell 1.21%.

Penumbra, Inc. received FDA clearance for its Lightning device to treat deep vein thrombosis. Boston Scientific Corp. agreed to acquire Penumbra in a cash and stock deal. Penumbra's stock may be affected by the acquisition and new product approval.

Boston Scientific (BSX) stock has potential for growth outside its WATCHMAN and electrophysiology businesses, which management expects to keep growing. The company's operating margin improved to 22.9% in Q2 2026, but management anticipates challenges in 2027 due to softness in WATCHMAN and electrophysiology. BSX trades at 17.8 times its past year's earnings, cheaper than the S&P 500, but with limited expected EPS growth in 2027.

Boston Scientific's AGENT, a paclitaxel-based drug-coated balloon (DCB), is the first of its kind approved in the U.S. for treating in-stent restenosis (ISR). Clinical trials show it reduces target lesion failure compared to uncoated balloons. AGENT is particularly effective in complex ISR cases, but sirolimus-based DCBs like SELUTION SLR may suit other patients. Boston Scientific is seeking expanded indications for AGENT.